Common Stock, par value $0.01 per share
- Symbol
- INSM
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 7.01, 9.01 · 8-K
Insmed Incorporated
INSMNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 5, 2026, Insmed Incorporated (the “Company”) announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor.…
Press release in this filing
Insmed Announces CFO Transition →Company context
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Current securities
Registered securities in this filing
INSMED INCORPORATED · 8-K · Filed 2026-10-05
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 5, 2026, Insmed Incorporated (the “Company”) announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from
the Company, effective October 30, 2026, and the Company has a search underway to identify a successor. The separation is not related to any disagreement between Ms. Bonstein and the Company on any matter relating to the Company’s accounting
practices, financial statements, internal controls or operations. Ms. Bonstein will receive the benefits set forth in Section 6.e of the Amended and Restated Employment Agreement between the Company and Ms. Bonstein dated April 1, 2022.
Item 7.01Item 7.01 - Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure.
On October 5, 2026, the Company issued a press release announcing the separation of Ms. Bonstein and providing certain guidance information for the
third quarter of 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 Insmed Announces CFO Transition - Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership - - Company Reaffirms Full-Year 2026 Financial Guidance - - Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026 - BRIDGEWATER, N.J., October 5, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Sara Bonstein will step down as Chief Financial Officer (CFO). Ms. Bonstein will continue to serve as CFO until October 30, 2026, to ensure a smooth transition through the Company’s reporting of its third-quarter 2026 financial results and she will participate in the earnings call on Thursday, October 29, 2026. Insmed has commenced a search to identify the Company’s next CFO. “We are grateful for Sara’s many contributions over the past almost seven years and her dedicated leadership overseeing our finance organization during a time when Insmed raised more than $4.2 billion in capital," said Will Lewis, Chair …
Open exhibit ↗